Lilly Launches Direct-to-Consumer Program for Diabetes, Migraine, Weight-Loss Drugs

In a move that sidesteps pharmacy benefit managers, Eli Lilly has launched a direct-to-consumer marketing program that will provide several of the company’s medicines for obesity, migraine, and diabetes at steeply discounted prices, and without the need for a face-to-face doctor visit.
Source: Drug Industry Daily